1
|
F-18 labeled vasoactive intestinal peptide analogue in the PET imaging of colon carcinoma in nude mice. BIOMED RESEARCH INTERNATIONAL 2013; 2013:420480. [PMID: 24459669 PMCID: PMC3888718 DOI: 10.1155/2013/420480] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/20/2013] [Revised: 11/29/2013] [Accepted: 11/29/2013] [Indexed: 11/17/2022]
Abstract
As large amount of vasoactive intestinal peptide (VIP) receptors are expressed in various tumors and VIP-related diseases, radiolabeled VIP provides a potential PET imaging agent for VIP receptor. However, structural modification of VIP is required before being radiolabeled and used for VIP receptor imaging due to its poor in vivo stability. As a VIP analogue, [R(8, 15, 21), L(17)]-VIP exhibited improved stability and receptor specificity in preliminary studies. In this study, F-18 labeled [R(8,15,21), L(17)]-VIP was produced with the radiochemical yield being as high as 33.6% ± 3% (decay-for-corrected, n = 5) achieved within 100 min, a specific activity of 255 GBq/ μmol, and a radiochemical purity as high as 99% as characterized by radioactive HPLC, TLC, and SDS-Page radioautography. A biodistribution study in normal mice also demonstrated fast elimination of F-18 labeled [R(8,15,21), L(17)]-VIP in the blood, liver, and gastrointestinal tracts. A further micro-PET imaging study in C26 colon carcinoma bearing mice confirmed the high tumor specificity, with the tumor/muscle radioactivity uptake ratio being as high as 3.03 at 60 min following injection, and no apparent radioactivity concentration in the intestinal tracts. In addition, blocking experiment and Western Blot test further confirmed its potential in PET imaging of VIP receptor-positive tumor.
Collapse
|
2
|
|
3
|
Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability. Eur J Pharm Biopharm 2009; 73:95-101. [PMID: 19481602 DOI: 10.1016/j.ejpb.2009.05.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2008] [Revised: 05/19/2009] [Accepted: 05/25/2009] [Indexed: 11/21/2022]
Abstract
Previously, [R(15,20,21), L(17)]-VIP-GRR (IK312532), a long-acting VIP derivative, was proposed as potential drug candidate for the treatment of asthma/COPD. The present work is aimed to elucidate solution-state stability of IK312532 and to develop further stabilized derivative with equipotent or higher biological functions. A stability study on IK312532 was carried out in solution state, and degradation mechanism was deduced by UPLC-MS and amino acid analyses. Three novel VIP derivatives were designed and chemically synthesized on the basis of stability data, being subjected to physicochemical and pharmacological characterization. Solution-state stability studies revealed the gradual degradation of IK312532, following pseudo-first-order kinetics. Chemical modification of IK312532, mainly position at 24, resulted in marked improvement of stability, although the chemical modification had no influence on the secondary structure, receptor binding, and activation of adenylate cyclase in rat lung cells. Novel derivatives also exhibited more potent neurite outgrowth in rat pheochromocytoma PC12 cells when compared to VIP and IK312532, possibly due to improved stability. Deamination of Asn at position 24 might be responsible for degradation of VIP derivative, and stability and chemical modification studies led us to the successful development of novel VIP derivatives with higher stability and biological functions.
Collapse
|
4
|
Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2008; 377:579-90. [DOI: 10.1007/s00210-007-0232-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2007] [Accepted: 11/23/2007] [Indexed: 12/23/2022]
|
5
|
Dufes C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier JC, Muller JM. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 2005; 285:77-85. [PMID: 15488681 DOI: 10.1016/j.ijpharm.2004.07.020] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2004] [Revised: 07/18/2004] [Accepted: 07/19/2004] [Indexed: 11/25/2022]
Abstract
The aim of this study was to evaluate glucose-bearing niosomes as a brain targeted delivery system for the vasoactive intestinal peptide (VIP). To this end, VIP/125I-VIP-loaded glucose-bearing niosomes were intravenously injected to mice. Brain uptake was determined by measuring the radioactivity of 125I-labeled VIP using gamma-counting, after intravenous administration of VIP in solution or encapsulated in glucose-bearing niosomes or in control niosomes. VIP integrity was assessed by reversed-phase HPLC analysis of brain extracts. Distribution of 125I-VIP derived radioactivity was examined from serial brain slices. HPLC analysis confirmed the presence of intact VIP in brain after administration of VIP-loaded niosomes, but not after administration of VIP solution. Encapsulation within glucose-bearing niosomes mainly allowed a significantly higher VIP brain uptake compared to control niosomes (up to 86%, 5min after treatment). Brain distribution of intact VIP after injection of glucose-bearing niosomes, indicated that radioactivity was preferentially located in the posterior and the anterior parts of the brain, whereas it was homogeneously distributed in the whole brain after the administration of control vesicles. In conclusion, this novel vesicular formulation of VIP delivers intact VIP to particular brain regions in mice. Glucose-bearing vesicles might be therefore a novel tool to deliver drugs across the blood-brain barrier (BBB).
Collapse
Affiliation(s)
- Christine Dufes
- Equipe de Biologie des Interactions Cellulaires, LBSC CNRS UMR 6558, Faculté des Sciences, Universite de Poitiers, 40 Avenue du Recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
6
|
Onoue S, Matsumoto A, Nagano Y, Ohshima K, Ohmori Y, Yamada S, Kimura R, Yajima T, Kashimoto K. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. Eur J Pharmacol 2004; 485:307-16. [PMID: 14757155 DOI: 10.1016/j.ejphar.2003.11.046] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The conformational properties of vasoactive intestinal peptide (VIP) include the N-terminal randomized structure and the C-terminal long alpha-helical structure. We have previously observed that the N-terminal random coil structure plays a crucial role in the receptor-selectivity. Here, to clarify how the formation of the alpha-helix plays a role in its biological functions, we chemically synthesized VIP analogues modified at the C-terminus, mid-chain, and N-terminus of the alpha-helical region, and evaluated the relationship between their alpha-helical contents and their biological activities including relaxant effects on murine stomach and receptor-binding activities. VIP and VIP-(1-27) showed equipotent biological activities with 48% and 50% alpha-helical content, respectively, each of which corresponds to 14 amino acid residues. VIP-(1-26) was 10% and threefold less potent in relaxant and binding activities, respectively, compared with VIP, and its 49% alpha-helical content resulted in 13 residues involved in the alpha-helix. Further truncation from 25 to 21 resulted in decrease in the alpha-helical content from 43% to 29%, corresponding residues from 11 to 6, the relaxant activity from 72% to 4%, and the affinity to the membrane from 60-fold to over 10(4)-fold less potency. In addition, disruption of the mid-chain and the N-terminus in the alpha-helical stretch by oxidation of Met(17) and deletion of Thr(11) also inhibited biological activities. These findings suggest that the presence of alpha-helical structure forming in 14 amino acid residues between position 10 and 23 in VIP is essential to its biological functions and the C-terminal amino acid residues between position 24 and 27 are requisite for this alpha-helical formation.
Collapse
Affiliation(s)
- Satomi Onoue
- Health Science Division, Itoham Foods Inc., 1-2-1 Kubogaoka, Moriya, Ibaraki 302-0104, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Tsueshita T, Gandhi S, Onyüksel H, Rubinstein I. Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1--38). J Appl Physiol (1985) 2002; 93:1377-83. [PMID: 12235038 DOI: 10.1152/japplphysiol.00277.2002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The purpose of this study was to elucidate the interactions between pituitary adenylate cyclase-activating peptide (PACAP)-(1--38) and phospholipids in vitro and to determine whether these phenomena modulate, in part, the vasorelaxant effects of the peptide in the intact peripheral microcirculation. We found that the critical micellar concentration of PACAP-(1--38) was 0.4-0.9 microM. PACAP-(1--38) significantly increased the surface tension of a dipalmitoylphosphatidylcholine monolayer and underwent conformational transition from predominantly random coil in saline to alpha-helix in the presence of distearoyl-phosphatidylethanolamine-polyethylene glycol (molecular mass of 2,000 Da) sterically stabilized phospholipid micelles (SSM) (P < 0.05). Using intravital microscopy, we found that aqueous PACAP-(1--38) evoked significant concentration-dependent vasodilation in the intact hamster cheek pouch that was significantly potentiated when PACAP-(1--38) was associated with SSM (P < 0.05). The vasorelaxant effects of aqueous PACAP-(1--38) were mediated predominantly by PACAP type 1 (PAC(1)) receptors, whereas those of PACAP-(1--38) in SSM predominantly by PACAP/vasoactive intestinal peptide type 1 and 2 (VPAC(1)/VPAC(2)) receptors. Collectively, these data indicate that PACAP-(1--38) self-associates and interacts avidly with phospholipids in vitro and that these phenomena amplify peptide vasoactivity in the intact peripheral microcirculation.
Collapse
Affiliation(s)
- Takaya Tsueshita
- Department of Biopharmaceutical Sciences, University of Illinois at Chicago, West Side Division, Chicago, Illinois 60612, USA
| | | | | | | |
Collapse
|
8
|
Gandhi S, Rubinstein I, Tsueshita T, Onyuksel H. Secretin self-assembles and interacts spontaneously with phospholipids in vitro. Peptides 2002; 23:201-4. [PMID: 11814635 DOI: 10.1016/s0196-9781(01)00596-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Secretin, a 27-amino acid neuropeptide, is a member of the secretin/glucagon/vasoactive intestinal polypeptide (VIP) superfamily of amphipathic peptides. The peptide modulates gastrointestinal and neuronal function and is currently being evaluated for the treatment of autism. However, as most peptides, it has a short circulation half-life. Previously, we have shown that VIP self-assembles in aqueous environment and interacts with a biomimetic phospholipid membrane. These in vitro characteristics increase VIP half-life and bioactivity in vivo. The purpose of this study was to investigate whether secretin exhibits similar properties in vitro by forming micelles in aqueous solution and interacting with phospholipids. Results of this study demonstrated that secretin self-assembles to form micelles in HEPES buffer at 25 degrees C above approximately 0.4 microM. Additionally, secretin interacts with a biomimetic phospholipid membrane as indicated from a significant increase in membrane surface pressure (from 25.5 +/- 1.3 to 32.5 +/- 3.0, P < 0.05). Importantly, the peptide undergoes conformational transition from predominantly random coil in saline to alpha-helix in the presence of phospholipid, distearoyl-phosphatidylcholine-poly(ethylene) glycol (mol mass 2000) micelles. We suggest that these distinct biophysical attributes could modulate secretin bioactivity in vivo.
Collapse
Affiliation(s)
- Salil Gandhi
- Department of Bioengineering, University of Illinois at Chicago, 60612, USA
| | | | | | | |
Collapse
|
9
|
Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 1995; 37:57-66. [PMID: 7893947 DOI: 10.1002/bip.360370203] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Analogs of vasoactive intestinal peptide (VIP) were synthesized and screened as bronchodilators with the ultimate goal of enhancing the potency and extending the duration of action of the native peptide. Several design approaches were applied to the problem. First, the amino acid residues required for receptor binding and activation were identified. A model of the active pharmacophore was developed. With knowledge of the secondary structure (NMR) of the peptide, various analogs were synthesized to stabilize alpha-helical conformations. Having achieved a level of enhanced bronchodilator potency, our approach then concentrated on identification of the sites of proteolytic degradation and synthesis of metabolically-stable analogs. Two primary cleavage sites on the VIP molecule were identified as the amide bonds between Ser25-Ile26 and Thr7-Asp8. This information was used to synthesize cyclic peptides which incorporated disulfide and lactam ring structures. Analog work combined the best multiple-substitution sites with potent cyclic compounds which resulted in identification of a cyclic lead peptide. This compound, Ro 25-1553, exhibited exceptionally high potency, metabolic stability, and a long duration of action and may be an effective therapeutic for the treatment of bronchospastic diseases.
Collapse
Affiliation(s)
- D R Bolin
- Roche Research Center, Hoffmann-La Roche, Inc., Nutley, New Jersey 07110
| | | | | | | |
Collapse
|
10
|
Leroux F, Goossens JF, Pommery N, Hénichart JP. A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells. REGULATORY PEPTIDES 1994; 52:119-28. [PMID: 7972935 DOI: 10.1016/0167-0115(94)90044-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
VIP is a widely distributed neuropeptide of 28 amino acids, whose central part is proposed to be an amphiphilic alpha-helix. In order to gain an understanding of the effect of this alpha helix on receptor binding and stimulation, a human VIP analog has been designed in which the residues 12 to 19 were replaced by a spacer of the same length, (gamma-aminobutyryl)2. This peptide altered neither the basal guinea pig tracheal smooth muscle tonus nor the VIP-induced relaxation. Conversely, the VIP analog was found to displace VIP from its binding sites on LA-N-2 human neuroblastoma cells (VIP IC50: 5.4 nM; VIP analog IC50: 52.2 nM) and to inhibit the VIP-induced cyclic AMP production of 58 +/- 15% at 1 microM and 95 +/- 2% at 10 microM. It seems that the alpha helix structure might only play the role of a spacer holding the important residues, at the N- and C-ends, respectively, at an appropriate distance. In the VIP analog structure, the (gamma-aminobutyryl)2 chain introduced in place of the alpha helix plays the role of adequate spacer to bind the LA-N-2 receptors but probably does not induce the active conformation for receptor stimulation. The lack of VIP analog effects on the tracheal receptors related to relaxation argues for a possible heterogeneity of VIP receptors on a pharmacological basis.
Collapse
Affiliation(s)
- F Leroux
- Institut de Chimie Pharmaceutique de Lille, Faculté des Sciences Pharmaceutiques et Biologiques, France
| | | | | | | |
Collapse
|
11
|
Noda Y, Rodriguez-Sierra J, Liu J, Landers D, Mori A, Paul S. Partitioning of vasoactive intestinal polypeptide into lipid bilayers. BIOCHIMICA ET BIOPHYSICA ACTA 1994; 1191:324-30. [PMID: 8172918 DOI: 10.1016/0005-2736(94)90183-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Incubation of radiolabeled vasoactive intestinal polypeptide (VIP) with preformed lipid vesicles composed of phosphatidylcholine, phosphatidylglycerol and cholesterol resulted in reversible and saturable association of the peptide with the lipid bilayer. The pH-optimum for the reaction was in the physiological range. The vesicle-associated peptide displayed enhanced stability to proteolytic digestion, it was efficiently released into the supernatant by detergent-solubilization of the vesicles but remained vesicle-associated during treatment with agents that disrupt ionic interactions. Peptide binding by electrically neutral vesicles was lower than that by negative vesicles. Electron spin resonance studies with 5-doxylstearic acid or 16-doxylstearic acid labeled vesicles suggested that VIP decreased the fluidity close to the surface of the bilayer and increased the fluidity in its hydrophobic core. These observations suggest that VIP can bind and penetrate lipid bilayers.
Collapse
Affiliation(s)
- Y Noda
- Department of Anesthesiology, University of Nebraska Medical Center, Omaha 68198-6830
| | | | | | | | | | | |
Collapse
|
12
|
Bolin DR, Cottrell J, Garippa R, O'Neill N, Simko B, O'Donnell M. Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1993; 41:124-32. [PMID: 8384606 DOI: 10.1111/j.1399-3011.1993.tb00122.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Analogs of vasoactive intestinal peptide with cysteine residues incorporated at selected sites within the sequence were prepared by solid phase methods, oxidized to the corresponding cyclic disulfides and purified to homogeneity by preparative HPLC. The cyclic compounds were assayed as smooth muscle relaxants on isolated guinea pig trachea, as bronchodilators in vivo in guinea pigs, and for binding to VIP receptors in guinea pig lung membranes. Of the analogs prepared at the N-terminus, one compound, Ac-[D-Cys6,D-Cys11,Lys12,Nle17,Val26,Th r28]-VIP, was found to be a full agonist with slightly more than one tenth the potency of native VIP. Most other cyclic analogs in the N-terminal region were found to be inactive. A second analog, Ac-[Lys12,Cys17,Val26,Cys28]-VIP, was also found to be a full agonist with potency about one third that of native VIP. Furthermore, this compound was active as a bronchodilator in vivo in guinea pig, but with somewhat diminished potency as compared to native VIP. Strikingly, this cyclic compound was found to have significantly longer duration of action (> 40 min) when compared to an analogous acyclic compound (5 min). The conformational restrictions imposed by formation of the cyclic ring structures may have stabilized the molecule to degradation, thus enhancing the effective duration of action. Analysis of this series of cyclic analogs has also yielded information about the requirements for the receptor-active conformation of VIP.
Collapse
Affiliation(s)
- D R Bolin
- Department of Peptide Research, Hoffmann-La Roche Inc., Nutley
| | | | | | | | | | | |
Collapse
|
13
|
Theriault Y, Boulanger Y, St-Pierre S. Structural determination of the vasoactive intestinal peptide by two-dimensional H-NMR spectroscopy. Biopolymers 1991; 31:459-64. [PMID: 1863695 DOI: 10.1002/bip.360310411] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The structure of the vasoactive intestinal peptide 1-28 in 40% 2,2,2-trifluoroethanol was investigated by two-dimensional 1H-nmr spectroscopy. All 1H resonances, except the gamma, delta, and epsilon protons of the lysine residues, could be sequentially assigned. Numerous intraresidual as well as short-range interresidual nuclear Overhauser effect spectroscopy connectivities were observed. Using a variable-target function minimization, a molecular model consisting of two helical stretches involving residues 7-15 and 19-27 connected by a region of undefined structure was calculated. The existence of an undefined structure between residues 16 and 18 confers mobility to the peptide molecule.
Collapse
Affiliation(s)
- Y Theriault
- Departement de chimie, Universite de Montreal, C.P. 6128, Succ. A, Montreal, Quebec H3C 3J7
| | | | | |
Collapse
|
14
|
Fry DC, Madison VS, Bolin DR, Greeley DN, Toome V, Wegrzynski BB. Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics. Biochemistry 1989; 28:2399-409. [PMID: 2730873 DOI: 10.1021/bi00432a010] [Citation(s) in RCA: 64] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Structures have been determined for a potent analogue of vasoactive intestinal peptide (VIP), Ac-[Lys12, Lys14, Nle17, Val26, Thr28]VIP (VIP'), in methanol/water solutions. In CD studies, both VIP and VIP' were helical in methanol/water, with the percentage of alpha-helix increasing with percentage methanol. The pH had little effect on the structure. Complete 1H NMR assignments were made for VIP' in 25% methanol at pH 4 and 6 and in 50% methanol at pH 6, using two-dimensional COSY, NOESY, and relay-COSY experiments. There were no widespread changes in chemical shifts between the samples at pH 4 and 6; however, widespread changes were observed between the samples in 25% and 50% methanol. Complete sets of NOEs were obtained for VIP' in 25% methanol, pH 4, and in 50% methanol, pH 6. These NOEs were converted into distance constraints and applied in molecular dynamics and energy minimization calculations using the program CHARMM. A set of low-energy structures was obtained for VIP' in each solvent system. In 25% methanol, VIP' has two helical segments at residues 9-17 and 23-28. The remainder of the structure is not well determined. In 50% methanol, residues 8-26 form a regular, well-defined alpha-helix and residues 5-8 form a type III beta-turn. The remaining residues are not ordered. These structural assessments agree with the CD data. In the lowest energy structure in 50% methanol, the side chains of Asp3, Phe6, Thr7, and Tyr10 are clustered together--these residues are conserved throughout the family of peptide hormones homologous to VIP.
Collapse
Affiliation(s)
- D C Fry
- Department of Physical Chemistry, Hoffmann-La Roche Inc., Nutley, New Jersey 07110
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
A variety of peptides have been proposed as transmitter candidates in non-cholinergic, non-adrenergic nerves. The nerves containing vasoactive intestinal polypeptide (VIP), which innervate blood vessels, non-vascular smooth muscle, mucosal epithelium and glands comprise a major and wide-spread population of the peptide-containing systems. There is now experimental data supporting the view that VIP is a transmitter in non-adrenergic, non-cholinergic nerves in the digestive tract, respiratory tract and urogenital tract, controlling smooth muscle tone and motility, blood flow and secretion. It is possible that impairment of VIP-containing nerves is involved in a number of autonomic dysfunctions.
Collapse
Affiliation(s)
- J Fahrenkrug
- Department of Clinical Chemistry, Bispebjerg Hospital, Copenhagen, Denmark
| |
Collapse
|
16
|
Affiliation(s)
- M Bodanszky
- Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106
| |
Collapse
|
17
|
Affiliation(s)
- V Mutt
- Department of Biochemistry II, Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
18
|
Fournier A, Saunders JK, Boulanger Y, St-Pierre SA. Conformational analysis of vasoactive intestinal peptide and related fragments. Ann N Y Acad Sci 1988; 527:51-67. [PMID: 3389647 DOI: 10.1111/j.1749-6632.1988.tb26972.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- A Fournier
- Institut National de la Recherche Scientifique-Santé, Université du Québec, Pointe-Claire, Canada
| | | | | | | |
Collapse
|
19
|
Staun-Olsen P, Ottesen B, Gammeltoft S, Fahrenkrug J. VIP binding sites on synaptosomes from rat cerebral cortex: structure-binding relationship. Peptides 1986; 7 Suppl 1:181-6. [PMID: 3018696 DOI: 10.1016/0196-9781(86)90183-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The structural requirements for VIP interaction with receptors on synaptosomes from rat cerebral cortex was investigated by the ability of VIP and VIP fragments, secretin analogues and fragments, peptides of the VIP/secretin family and several other regulatory peptides to inhibit specific 125I-VIP binding. Only large VIP fragments interacted with the VIP receptors with potencies relative to VIP ranging from 0.9-0.006%. The rank order of inhibition was: VIP 7-27 greater than VIP 11-28 greater than VIP 1-22-NH2 greater than VIP 16-28. Shorter fragments: VIP 18-28; VIP 18-28-NH2; VIP 19-28; VIP 21-28; VIP 22-28; VIP 1-18; VIP 1-18-NH2; VIP 1-10-NH2; VIP 1-6; VIP 16-20 and VIP 16-19 had no effect. Secretin fragments and analogues inhibited 125I-VIP binding with potencies of 2.2-0.01% relative to VIP in the order; secretin greater than (Ala4, Val5) secretin greater than (D-Ala4) secretin greater than (D-Phe6) secretin greater than secretin 5-27 greater than secretin 14-27. Other peptides of the VIP/secretin family inhibited 125I-VIP binding with potencies of 200-1%; avian VIP greater than porcine VIP greater than PHI = secretin greater than human GRF, whereas glucagon and GIP showed no inhibition. Among twenty-five other regulatory peptides only avian PP and somatostatin were inhibitors with relative potencies of 0.02% and 0.03%, respectively. In conclusion it may be emphasized that the intact VIP molecule is essential for VIP interaction with its receptors in the rat brain cortex.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
20
|
Rosselin G. The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity. Peptides 1986; 7 Suppl 1:89-100. [PMID: 3018707 DOI: 10.1016/0196-9781(86)90170-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A model is proposed for the receptors of the VIP family peptides including a ligand and a cellular domain. Specificities of the receptors are due to different ligand binding sites. Three subgroups of the family can be distinguished accordingly: glucagon and oxyntomodulin; GIP; VIP, secretin r and hGRF, PHI and PHM. In the same species, the expression of these different sites is cell-specific resulting in a stoichiometry of the ligand-receptor interaction which is compatible with physiological regulation of cell function. Specificities of the interaction as studied by native and synthetic analogs is supported both by restricted sequences of amino acids (such as that including the N-terminal histidine residue), and membrane-induced configuration of the ligand. Identity of the receptors is related to their interactions with subunits of the adenylate cyclase system. Arguments are put forward indicating that the alpha subunit of the guanyl regulatory protein is a reasonable candidate for directly transducing to the adenylyl cyclase the information contained in the activated ligand-binding site subunits. Evidence of functional and molecular heterogeneity of the recognizing site and of the alpha subunits leads to the supposition that some types of specific complementarity is retained at this level of interaction, further enhancing the possibility of species and cell differences. On the other hand, the identities found in other sequences of the alpha and ras oncogene products extend to the receptor of the VIP family peptides a pattern of organization which is similar to that recently described for the insulin family of receptors. The role of ligand specific receptor mediated regulation in homologous or heterologous desensitization is reviewed in brief for the peptides of the VIP family as well as the appearance of the specific receptor during the ontogenesis or the cell differentiation. The co-distribution of plasma membrane receptors from other families further adds to the cell specificity resulting for each differentiated cell in unique patterns of recognizing site. Some examples of receptor-receptor interaction are given, indicating that the integration of the different signals by cells might occur at an early step through the transmembranair domain of the receptor.
Collapse
|
21
|
Abstract
The significance of a well defined molecular architecture in hormone receptor interaction and the methods available for the study of preferred conformations are discussed. The conformational freedom in glucagon is a major obstacle in the determination of its biologically relevant geometry. In the secretin molecule intramolecular forces generate a folded, partially helical conformation. In respect of long range cooperative interactions resulting in a compact molecule with secondary-tertiary structure secretin is similar to globular proteins. In VIP some characteristics of secretin and also of glucagon can be recognized. Further progress in conformation analysis can be expected from the study of rigid, cyclic analogs in which the biological activities of the parent hormones are retained or even enhanced. Such analogs have well defined conformations without external stabilization from membrane mimicking lipids. Therefore, they provide information on the biologically relevant geometry of the hormones and contribute also to our knowledge of receptor sites.
Collapse
|
22
|
Marvaldi J, Luis J, Muller JM, el Battari A, Fantini J, Martin JM, Abadie B, Tirard A, Pichon J. Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approach. Peptides 1986; 7 Suppl 1:137-45. [PMID: 3018691 DOI: 10.1016/0196-9781(86)90176-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The initial event of VIP action is its interaction with a specific receptor at the surface of a target cell. The understanding of the fine mechanism of action of VIP requires the characterization and of course the purification of the receptor. The understanding of the mechanism which regulates the number of receptor sites at the cell surface, if it occurs, is also a way to characterize the properties of VIP receptor. In this paper we report a number of data which represent several attempts to characterize VIP receptor in a human colonic adenocarcinoma cell (HT 29 cells). We have characterized a monoclonal antibody which partially inhibits 125I-VIP binding to HT 29 cells. We have specifically cross-linked, on intact HT 29 cells, a major polypeptide of Mr-64,000 with 125I-VIP using DTSP or DSS as cross-linking reagents. This polypeptide behaves like a high affinity binding site for VIP. We have demonstrated that VIP is rapidly internalized in HT 29 cells (in less than 10 minutes) and that simultaneously VIP receptors were no more detectable on the cell surface by cross-linking experiments. This suggests that VIP is internalized together with its receptor.
Collapse
|
23
|
Barnette MS, Weiss B. Inhibition of calmodulin-stimulated phosphodiesterase activity by vasoactive intestinal peptide. J Neurochem 1985; 45:640-3. [PMID: 2989433 DOI: 10.1111/j.1471-4159.1985.tb04036.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The effects of certain peptides of the glucagon family on calmodulin activity were determined from their capacity to inhibit a calmodulin-dependent form of phosphodiesterase. Vasoactive intestinal peptide and secretin were potent inhibitors of calmodulin activity, having IC50 values of 0.5 microM and 2 microM, respectively. By contrast, glucagon failed to inhibit calmodulin activity even at concentrations of 100 microM. None of these compounds significantly inhibited the basal activity of phosphodiesterase at concentrations up to 100 microM. These findings support the suggestion that important structural features of peptides for anticalmodulin activity include a net positive charge and a hydrophobic surface.
Collapse
|
24
|
Role of phospholipids in the binding activity of vasoactive intestinal peptide receptors. EXPERIENTIA 1985; 41:631-3. [PMID: 2987022 DOI: 10.1007/bf02007693] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Phospholipase digestion of rat intestinal epithelial cell membranes was performed in order to study the influence of membrane phospholipids on the binding activity of VIP receptors. Phospholipases A2 and C strongly (ED50 congruent to 4 X 10(-2) and 4 X 10(-1) micrograms/ml, respectively) and rapidly reduced 125I-VIP binding to membranes whereas phospholipase D was ineffective. This suggests an important role of both hydrophobic and hydrophilic groups of phospholipids on VIP receptor binding activity.
Collapse
|
25
|
Fournier A, Saunders JK, St-Pierre S. Synthesis, conformational studies and biological activities of VIP and related fragments. Peptides 1984; 5:169-77. [PMID: 6473150 DOI: 10.1016/0196-9781(84)90202-x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
VIP and related fragments were prepared by the solid-phase method. The peptides were assembled on a benzhydrylamine resin and couplings of the Boc-amino acids were carried out by the symmetrical anhydride method. Cleavage was achieved by treatment with liquid HF and purification was accomplished by successive steps of cation exchange, partition and semi-preparative high pressure liquid chromatography. The biological activities were evaluated in vitro in the rabbit perfused heart and in vivo on the rat blood pressure. Structural studies were performed by high resolution (400 MHz) 1H-NMR spectroscopy and circular dichroism. The results show that among all the fragments tested, only VIP2-28 retains significant biological activity. The fragments 1-14 and 15-28, which are devoid of activity, were found to be inactive as antagonists. VIP and some of the fragments tend to adopt the helical structure, as demonstrated by spectroscopic techniques.
Collapse
|
26
|
Hamed MM, Mattice WL. Mean-square hydrophobic moment for partially helical polypeptides. Biopolymers 1984. [DOI: 10.1002/bip.360230204] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
27
|
Ottesen B. Vasoactive intestinal polypeptide as a neurotransmitter in the female genital tract. Am J Obstet Gynecol 1983; 147:208-24. [PMID: 6137145 DOI: 10.1016/0002-9378(83)90117-5] [Citation(s) in RCA: 70] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Vasoactive intestinal polypeptide (VIP) has been demonstrated in nerve fibers of the female genital tract localized in synaptic vesicles. The VIP-containing nerve fibers seem to innervate nonvascular smooth muscle, blood vessels, and epithelial cells. Evidence is accumulating that VIP fulfills a number of the classical criteria to be a neurotransmitter in the female genital tract. It is likely that VIP is the mediator of genital functions, which are controlled by noncholinergic, nonadrenergic nerve fibers. VIP seems to play a role in the local nervous control of uterine smooth muscle, e.g., opening of the uterotubal junctions, and to be involved in vasodilatation in the uterus as wells as the vagina. In conclusion, a third or peptidergic division of the autonomic nervous system seems to participate in the nervous control of reproduction.
Collapse
|
28
|
Fahrenkrug J, Gammeltoft S, Staun-Olsen P, Ottesen B, Sjöquist A. Multiplicity of receptors for vasoactive intestinal polypeptide (VIP): differential effects of apamin on binding in brain, uterus and liver. Peptides 1983; 4:133-6. [PMID: 6312430 DOI: 10.1016/0196-9781(83)90102-x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Apamin is a neurotoxic octadecapeptide from bee venom, which has been shown to inhibit the non-adrenergic, non-cholinergic inhibitory innervation of the smooth muscle of the gut. Since vasoactive intestinal polypeptide (VIP) has been proposed as a possible inhibitory neurotransmitter, the effect of apamin on the receptor binding of 125I-VIP was studied using the following assays: (1) isolated synaptosomes from rat cerebral cortex, (2) crude plasma membranes from hog uterine smooth muscle, and (3) purified plasma membranes and isolated hepatocytes from hog liver. Apamin inhibited the receptor-bound 125I-VIP on membranes from brain or myometrium, although the binding affinity was 100-1000 times lower than for VIP. The displacement curves for VIP and apamin were parallel suggesting that apamin interacts with both the low and high affinity VIP receptors. In membranes and cells from liver, apamin was unable to displace receptor-bound 125I-VIP in concentrations up to 50 mumol/l. The findings suggest that the VIP receptors in liver are different from those in the brain cortex and myometrium.
Collapse
|
29
|
Abstract
VIP is a neuroregulator occurring in the central and peripheral nervous system which exhibits the function of neurotransmitter in the brain, neuroendocrine substance at the pituitary level, and neuroparacrine substance in peripheral organs. The structure and the specificity of the molecule as studied by antibody and receptor, and its location in brain and peripheral organs are summarized as well as its numerous biological effects. The method used to demonstrate the involvement of VIP in a physiological regulation is described and illustrated by two examples: the effect of VIP on gut epithelium and the neuroendocrine action of VIP in inducing prolactin release from pituitary cells. The consequence of this recent progress in the knowledge of VIP release and action in human physiology and disease is indicated.
Collapse
|
30
|
Robinson RM, Blakeney EW, Mattice WL. Lipid-induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide. Biopolymers 1982; 21:1271-28. [PMID: 7093437 DOI: 10.1002/bip.360210615] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
31
|
Amiya T, Kajiwara K, Miyamoto T, Inagaki H. Conformational studies of the α-helical proteins from wool keratin by c.d. Int J Biol Macromol 1982. [DOI: 10.1016/0141-8130(82)90047-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Mutt V. Chemistry of the gastrointestinal hormones and hormone-like peptides and a sketch of their physiology and pharmacology. VITAMINS AND HORMONES 1982; 39:231-427. [PMID: 6755887 DOI: 10.1016/s0083-6729(08)61138-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
33
|
Laburthe M, Prieto JC, Amiranoff B, Dupont C, Hui Bon Hoa D, Rosselin G. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 2. Characterization and structural requirements of the stimulatory effect of vasoactive intestinal peptide on production of adenosine 3':5'-monophosphate. EUROPEAN JOURNAL OF BIOCHEMISTRY 1979; 96:239-48. [PMID: 88368 DOI: 10.1111/j.1432-1033.1979.tb13034.x] [Citation(s) in RCA: 117] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Porcine vasoactive intestinal peptide stimulated adenosine 3':5'-monophosphate (cyclic AMP) production in rat intestinal epithelial cells. The stimulation was dependent on time and temperature and was potentiated by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. Under optimal conditions (at 15 degrees C, with 0.2 mM 3-isobutyl-1-methylaxanthine, at a cell concentration up to 18 microgram DNA/ml), the cyclic AMP production produced by vasoactive intestinal peptide was constant for 10 min and stopped after 15 min incubation, at either low (1 nM) or high (30 nM) concentration of the peptide. This plateau effect was demonstrated not to be due to an inactivation of vasoactive intestinal peptide in the medium nor to an alteration of receptors for the peptide. Cyclic AMP production was sensitive to a concentration as low as 0.1 nM vasoactive intestinal peptide. Maximal stimulation of cyclic AMP levels by vasoactive intestinal peptide was observed with 30 nM vasoactive intestinal peptide and represented an 11-fold increased above basal. The dorse-response curve was monophasic with a Km of 2.3 x 10(-9) M. No cooperative effects were detected by Hill analysis. The positive non-linear relationship observed between stimulation of cyclic AMP production and occupancy of binding site was not time-dependent as indicated by experiments performed after 15, 45 and 120 min incubation. Maximal and half-maximal responses were obtained at about 70% and 7% occupation of binding sites, respectively. Chicken vasoactive intestinal peptide and porcine secretin were agonists of porcine vasoactive intestinal peptide with a 6-times and a 120-times lower potency, respectively. Among secretin analogs that were found to have low affinity for vasoactive intestinal peptide binding sites, [4-alanine, 5-valine]secretin, that resembles vasoactive intestinal peptide at the first seven amino acids at the N-terminal end, was a partial agonist of vasoactive peptide at the first seven amino acids at the N-terminal end, was a partial agonist of vasoactive intestinal peptide and others failed to stimulate cyclic AMP production. Glucagon (10microM), gastric inhibitory peptide (0.1 microM), substance, P, neurotensin, octapeptide of cholecystokinin, bovine pancreatic polypeptide, human gastrin I with leucine at residue 15, Leu-enkephalinand somatostatin (1 microM) did not alter cyclicAMP levels. Non-peptide mediators such as dopamine, serotonin, acetylcholine and histamine, tested at 10 microM, were also ineffective. Prostaglandins E2, E1 and isoproterenol, tested at 10 microM, induced an increase of cyclic AMP levels above basal but were 9.5, 13.7 and 17.5 times less efficient than vasoactive intestinal peptide, respectively. Thus vasoactive intestinal peptide is a unique stimulus of cyclic AMP production in rat intestinal epithelial cells.
Collapse
|
34
|
Prieto JC, Laburthe M, Rosselin G. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 1. Characterization, quantitative aspects and structural requirements of binding sites. EUROPEAN JOURNAL OF BIOCHEMISTRY 1979; 96:229-37. [PMID: 37084 DOI: 10.1111/j.1432-1033.1979.tb13033.x] [Citation(s) in RCA: 140] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
35
|
Abstract
An examination of a series of peptides corresponding to partial sequences of secretin and the application of empirical conformational parameters to the sequence has reopened the question about the position of the short helical stretch in the folded chain. In earlier studies, this was tentatively placed near the N-terminus, while newly accumulated evidence points to the C-terminal area. The possible role of ion pairs in the stabilization of the folding was investigated by the preparation and examination of synthetic analogues of the C-terminal tricosapeptide part of secretin. The carboxyl groups of glutamic acid (in position 9) and of aspartic acid (in position 15) were replaced by carboxamides. The 9-glutamine and the 15-asparagine analogues show a significant decrease in helical character. This loss of "structure" is even more pronounced in the 9-glutamine-15-asparagine tricosapeptide. Thus, ion-pair formation is indeed implicated as one of the forces which stabilize the folded conformation of the chain. Possible correlations between biological activity and secretin-like architecture were studied on several smooth muscle preparations.
Collapse
|
36
|
Moroder L, Filippi B, Borin G, Marchiori F. Studies on cytochrome c. XI. Circular dichroism studies on synthetic peptides related to the C-terminal region of baker's yeast iso-1-cytochrome c. Biopolymers 1975. [DOI: 10.1002/bip.1975.360141008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|